- 8.1k views
Use of Oral Glycemic Drugs in CKD
The use of oral glycemic drugs in patients with Chronic Kidney Disease (CKD) requires careful consideration due to altered drug metabolism and excretion associated with kidney dysfunction. Metformin, often the first-line treatment for type 2 diabetes, may be used with caution in mild to moderate CKD but is contraindicated in advanced stages due to the risk of lactic acidosis. Sulfonylureas, except for gliclazide and glimepiride, are generally avoided in CKD because of the prolonged hypoglycemia risk. DPP-4 inhibitors are safer options but may require dose adjustments based on renal function. SGLT2 inhibitors, beneficial for their cardiovascular and renal protective effects, are increasingly recommended, though some are contraindicated in severe CKD. GLP-1 receptor agonists offer a safer profile for CKD patients, with liraglutide and semaglutide being viable options. Ultimately, individualized treatment, frequent monitoring, and adjustments of oral hypoglycemic agents are crucial in managing diabetes in CKD patients.
About the Speaker
Dr. Adarsh K.S.
Consultant in Dept of Endocrinology, Manipal Hospitals,Bangalore
Adarsh K S is a distinguished Consultant in the Department of Endocrinology at Manipal Hospitals in Bangalore, with an extensive educational background comprising an MBBS, MD in Medicine, and a DM in Endocrinology from some of India's prestigious institutes.
Upcoming Case Discussions
H. pylori Treatment with PYELRA®: Best Practices
PYLERA® is a medication used for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of stomach ulcers and gastritis. It contains a combination of three active ingredients: bismuth subcitrate potassium, metronidazole, and tetracycline. This combination works synergistically to eradicate H. pylori bacteria and reduce associated symptoms. Treatment with PYLERA® typically involves taking multiple capsules four times a day for a specified duration, as prescribed by a healthcare provider. It is important to follow the treatment regimen as directed and to discuss potential side effects
Pneumonia in Children
Pneumonia in children is often caused by viral or bacterial infections, leading to inflammation of the lungs. Symptoms may include cough, fever, rapid breathing, and chest pain. Diagnosis typically involves physical examination, chest X-ray, and sometimes blood tests or other imaging studies. Treatment may include antibiotics for bacterial pneumonia, supportive care such as rest, fluids, and fever management, and in severe cases, hospitalization for oxygen therapy and close monitoring. Vaccination against common pathogens like Streptococcus pneumoniae and Haemophilus influenzae type b can help prevent pneumonia in children.
New Developments in Interventional Cardiology
Recent advancements in interventional cardiology have witnessed the evolution of cutting-edge techniques and technologies aimed at improving patient outcomes. From innovative stent designs to refined imaging modalities and minimally invasive procedures, interventional cardiologists now have a broader arsenal to address complex coronary artery disease. Drug-eluting stents with novel coatings aim to reduce restenosis rates, while bioresorbable scaffolds offer the promise of temporary vessel support without long-term metal implantation. Moreover, advances in imaging, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), enable more precise lesion assessment and optimized stent placement. Additionally, the advent of transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, offering a less invasive option for high-risk patients. These developments underscore the continuous pursuit of innovation in interventional cardiology, striving for enhanced patient care, and improved long-term outcomes.
Alcoholic Hepatitis: Management Strategies
Management of alcoholic hepatitis involves a comprehensive approach aimed at halting disease progression, managing symptoms, and promoting liver recovery. The cornerstone of treatment involves complete alcohol cessation to prevent further liver damage and promote healing. Patients often have malnutrition, so nutritional therapy with a focus on adequate protein intake and vitamin supplementation is crucial. Corticosteroids like prednisolone may be prescribed in severe cases to reduce liver inflammation and improve survival rates. In severe cases unresponsive to medical therapy, liver transplantation may be considered, although strict criteria must be met. Diuretics may be used cautiously to manage ascites while monitoring for renal function. Prophylactic measures such as beta-blockers may be used to reduce the risk of variceal bleeding.
Patient Centric Care in Critical Care
Patient-centric care in critical care is a holistic approach that places the patient at the center of medical decision-making and treatment processes. It prioritizes the individual's preferences, values, and needs, considering not only their medical condition but also their emotional and psychological well-being. This approach involves clear communication, shared decision-making, and active involvement of patients and their families in care planning. Healthcare providers strive to deliver personalized care that respects the patient's dignity, autonomy, and cultural beliefs, aiming to optimize outcomes and enhance overall quality of life.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Adarsh K.S. 's Talks on Assimilate
- 30th-January-2024, TIME : 5:00PM - 6:00PM
- 0
The use of oral glycemic drugs in patients with Chronic Kidney Disease (CKD) requires careful consideration due to altered drug metabolism and excretion associated with kidney dysfunction. Metformin, often the first-line treatment for type 2 diabetes, may be used with caution in mild to moderate CKD but is contraindicated in advanced stages due to the risk of lactic acidosis. Sulfonylureas, except for gliclazide and glimepiride, are generally avoided in CKD because of the prolonged hypoglycemia risk. DPP-4 inhibitors are safer options but may require dose adjustments based on renal function. SGLT2 inhibitors, beneficial for their cardiovascular and renal protective effects, are increasingly recommended, though some are contraindicated in severe CKD. GLP-1 receptor agonists offer a safer profile for CKD patients, with liraglutide and semaglutide being viable options. Ultimately, individualized treatment, frequent monitoring, and adjustments of oral hypoglycemic agents are crucial in managing diabetes in CKD patients.